MEDIDELIC

Biotechnology research; Research and development in the pharmaceutical, bioenergetic imprinting and biotechnology fields; Providing information on the subject of scientific research in the field of biochemistry, biological signaling and biotechnology; Development of new technology for others in the field of biotechnology; Scientific Research and Development of Absorption, Distribution, Metabolism, Excretion and Toxicity (ADMET) modeling, physiologically based pharmacokinetic (PBPK) and physiologically based biopharmaceutics (PBBM) modeling and simulation software for the pharmaceutical and biotechnology industries; Research and Development of software that allows pharmaceutical scientists to predict certain key potential endpoints and dynamics, in silico, thereby reducing research and development costs and helping clients make better projects decisions sooner that includes PBBK (Physical based pharmacokinetics), PBBM (Physiologically based biopharmaceutics), NOAEL (No observed adverse effect level); Scientific Research and Development utilizing a proprietary algorithm and artificial intelligence that utilizes a combination of lifestyle, hospitalization, emergency room use, mortality and outcomes data to assist the healthcare industry and workers in identifying groups at high risk and populations that can benefit from various therapeutic approaches; Scientific Research and Development of drugs and therapies through applying interactive maps that identify ideal target populations for various therapeutic approaches including the mapping of surfaces that apply socio, economic and environmental factors such as access to or lack of access to transportation or nutritious food, or exposure to high stress and artificial intelligence analysis considering the suitability of various drugs or therapies